Enhancing the efficacy of immunotherapy in non-small cell lung cancer using an RGD-mimetic

Queen Mary scientists led by Prof Kairbaan Hodivala-Dilke have invented a new methodology for treating lung cancer – the leading cause of cancer deaths worldwide.

Most lung cancer patients already have advanced stage cancer when diagnosed. These advanced cancers are inoperable and respond poorly to anti-cancer treatments.

This new invention improves the efficacy of immunotherapy and chemotherapy – which currently work for less than a third of lung cancer patients, and add barely a year of life expectancy.

The treatment works by co-administering an αvβ3- and/or αvβ5-integrin targeting agent alongside the immunotherapy/chemotherapy. Early tests show this method can reduce the tumour burden, extend survival, and allow for lower does of immunotherapy/chemotherapy – thereby reducing side effects.

We’re looking for a partner to help us develop this treatment further.


Dr Mark Gurden –


Professor Kairbaan Hodivala-Dilke, BSc, PhD, FMedSci.

Barts Cancer Institute, Faculty of Medicine and Dentistry, Queen Mary University of London.

More from our pipeline

Predicting dementia nine years before symptoms

Restorative treatments for osteoarthritis

Repurposing an anti-cancer agent for heart failure